Recent Updates
Recently added Catalysts

Astral

Phase 3

Upper Airway Obstruction | Unknown | Other |ResMed Inc.|Last Updated: Jul 26, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment42
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02683772Astral VAPS AutoEPAP Clinical TrialPHASE3 COMPLETED 42Apr 15, 2016Jul 6, 2017Jul 26, 20195 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Oxygen Desaturation Index 4% (ODI4%)
Overnight, up to 8 hrs on nights 1 and 2

Mean paired difference AutoEPAP-manual EPAP: Comparison of Oxygen Desaturation Index 4% (ODI4%) values between groups by using mean ODI4% (#events/hour). A cross-over analysis was generated to investigate the influence of a possible period effect on the primary endpoint, paired change in ODI4% between Auto and manual EPAP

Secondary Endpoints
Sleep Efficiency (%)
Overnight, up to 8 hrs on nights 1 and 2
Apnea Hypopnea Index (AHI)
Overnight, up 8 hrs on night 1 and 2
Nadir Arterial Oxygen Saturation (SpO2)
Overnight, up 8 hrs on night 1 and 2
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
iVAPS with AutoEPAPEXPERIMENTALThis is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
iVAPS with manual EPAPACTIVE_COMPARATORThis is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
Interventions
NameTypeDescription
AstralDEVICEAstral ventilator
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion criteria for the study are: 1. Participant has ability to provide written informed consent 2. Participants aged ≥18 years old 3. Participant has documented respiratory failure (e.g. sleep hypoventilation with historical PtCO2 increase ≥ 10mmHg) and/or daytime hypercapnia (\>45 mmHg) 4. Pa...

Countries:United States
Unlock Eligibility Criteria